PMC8238617_01
PMC8238617_02
PET/CT comparison after 4 weekly dose of rituximab. Pretreatment PET/CT (a) showing FDG-avid splenomegaly. PET/CT after 4 weekly doses of rituximab 375 mg/m2 (b), demonstrating a complete response.
CRII2021-6587323.001.jpg
PMC8238617_02_CRII2021-6587323.001.jpg
fig1
He received a risk-stratified approach with rituximab 375 mg/m2 weekly for four weeks followed by a PET/CT scan showing a complete response (Figure 1).
Epstein-Barr virus (EBV) viral loads over time. Day 0 is defined as the day of diagnosis with EBV-positive lymphoproliferative disorder. EBV DNA quantification from the peripheral blood at various time points before and after starting rituximab therapy. C1D1 = cycle 1, day 1 of rituximab. EBV quantification was undetectable after 60 days following the start of rituximab therapy.
CRII2021-6587323.002.jpg
PMC8238617_02_CRII2021-6587323.002.jpg
fig2
His EBV viremia cleared four months after starting therapy, (Figure 2). He remains in a complete remission from his EBV lymphoproliferative disorder and HLH for over 14 months.